Yonal Ipek, Hindilerden Fehmi, Ozcan Erkan, Palanduz Sukru, Aktan Melih
Istanbul University Istanbul Medical Faculty, Department of Internal Medicine, Division of Hematology, Istanbul, Turkey.
J Med Case Rep. 2012 Feb 16;6:67. doi: 10.1186/1752-1947-6-67.
Therapy-related acute myeloid leukemia occurs as a complication of treatment with chemotherapy, radiotherapy, immunosuppressive agents or exposure to environmental carcinogens.
We report a case of therapy-related acute myeloid leukemia in a 37-year-old Turkish woman in complete remission from breast cancer. Our patient presented to our facility with fatigue, fever, sore throat, peripheral lymphadenopathy, and moderate hepatosplenomegaly. On peripheral blood and bone marrow aspirate smears, monoblasts were present. Immunophenotypic analysis of the bone marrow showed expression of CD11b, CD13, CD14, CD15, CD33, CD34, CD45 and human leukocyte antigen-DR, findings compatible with the diagnosis of acute monoblastic leukemia (French-American-British classification M5a). Therapy-related acute myeloid leukemia developed three years after adjuvant chemotherapy consisting of an alkylating agent, cyclophosphamide and DNA topoisomerase II inhibitor, doxorubicin and adjuvant radiotherapy. Cytogenetic analysis revealed a 46, XX, deletion 7 (q22q34), deletion 20 (q11.2q13.1) karyotype in five out of 20 metaphases and inversion 16 was detected by fluorescence in situhybridization. There was no response to chemotherapy (cytarabine and idarubicin, FLAG-IDA protocol, azacitidine) and our patient died in the 11th month after diagnosis.
The median survival in therapy-related acute myeloid leukemia is shorter compared to de novoacute myeloid leukemia. Also, the response to therapy is poor. In therapy-related acute myeloid leukemia, complex karyotypes have been associated with abnormalities of chromosome 5, rather than 7. To the best of our knowledge, this is the first case of therapy-related acute myeloid leukemia showing the co-presence of deletion 7q, 20q and the inversion 16 signal.
治疗相关的急性髓系白血病是化疗、放疗、免疫抑制剂治疗或接触环境致癌物后的并发症。
我们报告一例37岁的土耳其女性患者,该患者乳腺癌已完全缓解,却发生了治疗相关的急性髓系白血病。我们的患者因疲劳、发热、咽痛、外周淋巴结肿大和中度肝脾肿大前来我院就诊。外周血和骨髓涂片可见原单核细胞。骨髓免疫表型分析显示CD11b、CD13、CD14、CD15、CD33、CD34、CD45和人类白细胞抗原-DR表达,这些结果符合急性单核细胞白血病(法美英分类M5a)的诊断。治疗相关的急性髓系白血病发生在辅助化疗三年后,辅助化疗包括烷化剂环磷酰胺、DNA拓扑异构酶II抑制剂阿霉素及辅助放疗。细胞遗传学分析显示,20个中期细胞中有5个的核型为46, XX, 7号染色体缺失(q22q34)、20号染色体缺失(q11.2q13.1),荧光原位杂交检测到16号染色体倒位。化疗(阿糖胞苷和伊达比星,FLAG-IDA方案,阿扎胞苷)无效,患者在诊断后第11个月死亡。
与原发性急性髓系白血病相比,治疗相关的急性髓系白血病中位生存期较短。而且,对治疗的反应较差。在治疗相关的急性髓系白血病中,复杂核型与5号染色体异常有关而非7号染色体。据我们所知,这是首例显示7q、20q缺失及16号染色体倒位信号同时存在的治疗相关急性髓系白血病病例。